Treatment of Prostate Cancer With Firmagon®

United Clinic Management GmbH100 enrolled

Overview

How are testosterone levels of patients with prostate cancer under treatment with Firmagon® changing. Former studies showed a quick fall of testosterone levels after start of therapy with Firmagon® and a quick recovery when therapy is stopped. The investigators want to prove this in a normal outpatient urologist setting. Furthermore data is collected to prove the adherence to the German S3-Guideline for the treatment of prostate cancer.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Prostate Cancer

Interventions

DegarelixDRUG

subcutaneous injection

Eligibility

Sex: MALEMin age: 18 YearsMax age: 95 Years

Medical Language ↔ Plain English

Inclusion Criteria: * advanced hormone-dependent prostate cancer with no other previous hormone therapy for whom - irrespectively of this NIS -the use of Firmagon® is intended Exclusion Criteria: * contraindication for Degarelix

Locations (1)

UCM GmbH

Planegg, Bavaria, Germany

Outcomes

Primary Outcomes

PSA-/Testosterone Level

Time frame: 12 months

Secondary Outcomes

S3 Guideline

Percentage of patients who have been treated in accordance with the grade A recommendations of the S3 guideline for treatment of prostate cancer

Time frame: 12 months

Anxiety

Anxiety score

Time frame: 12 Months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.